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Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by a progres-
sive death of motor neurons for which there is no cure or effective treatment. The cause of ALS and the 
specific mechanisms of neuronal death remain unknown. However, considerable evidence supports 
the existence of autoimmune mechanisms contributing to pathogenesis in ALS, including biochemi-
cal, morphological, pharmacological, and physiological studies performed in animal models, cell 
culture, or with ex vivo preparations (1–6). Typical hallmarks of autoimmunity, such as circulating 
immune complexes, higher frequency of a particular histocompatibility type, or association with 
other autoimmune diseases, have also been reported (7, 8). An important marker of autoimmunity 
is the degree of T-lymphocytic infiltration in the anterior horn of the spinal cord from ALS patients 
(9, 10). Using monoclonal antibodies against T-cells, B-cells, and macrophages, almost 80% of the 
specimens show a cellular mononuclear infiltration. The cellular composition of the spinal cord 
inflammation consists of subsets of suppressor or cytotoxic T-cells and macrophages in the anterior 
and lateral corticospinal tracts and anterior horns (10). T-helper cells are also observed in proximity 
to corticospinal tract degeneration (11). Hence, inflammation in ALS spinal cord and brain appears 
to be primarily due to T-cells and macrophages (12), and aberrant macrophage activity is believed 
by many investigators to contribute to the pathology underlying ALS. This may explain the recent 
promising results of an ALS phase 2 clinical trial of NP001, a regulator of inflammatory macrophage 
activity (13). Although the predefined endpoints in this study did not reach statistical significance, 
administration of NP001 was associated with cessation in disease progression in 27% of patients, 
approximately 2.5 times greater than the percentage in patients on placebo. Two major plasma 
markers of inflammation, interleukin-18 (IL-18) and lipopolysaccharide (LPS), differentiated NP001 
responders from non-responders, suggesting that the subgroup of patients with greater baseline 
biomarkers of neuroinflammation experienced the most benefit (13). Additional evidence pointing 
toward pathologic involvement of autoimmune processes has been the finding that immunoglobu-
lins from ALS patients have been shown to cause apoptosis of motor neurons in primary spinal cord 
cultures (14) and that passive transfer of immunoglobulins to mice caused abnormalities at motor 
end-plates and degeneration of motor neurons (4, 15). These findings suggest that antibodies can 
contribute to disease pathogenesis. Increased levels of interleukins IL-17 and IL-23 have also been 
found in serum and cerebrospinal fluid of ALS patients (16). This increment is thought to be a sign 
of T-helper 17 (Th17) activation, a subset of T-cells suggested to be crucial in destructive autoim-
munity. Astrocytes have also been shown to participate in the pathogenesis of ALS by producing a 
microenvironment toxic to motor neurons through increased neuroinflammation, oxidative damage, 
February 2016 | Volume 7 | Article 122
Leis et al. Immunoablation in Amyotrophic Lateral Sclerosis
Frontiers in Neurology | www.frontiersin.org
and glutamate excitotoxicity (17, 18). Overactivated astroglia 
produce high levels of protein S100B and other proinflammatory 
factors, which exacerbate neuroinflammation. The extracellular 
effects of S100B vary, depending on the concentration attained; 
at nanomolar concentrations, S100B is trophic to neurons, but 
at micromolar concentrations, S100B causes neuronal apoptosis 
(19, 20). Many of the effects of S100B on neurons are transduced 
by the receptor for advanced glycation end-products (RAGE), 
which participates in the pathophysiology of brain inflammatory 
disorders by regulating several inflammation-related events, 
including activation and migration of microglia and neutrophils 
to inflammatory sites (19–21). Extravasation of S100B into the 
systemic circulation can also trigger a pathologic autoimmune 
reaction with circulating antibodies that may re-enter the CNS 
to initiate an autoimmune response (22). Hence, S100B can 
be viewed as an astrocytic endokine that can act as an immu-
noregulator to participate in inflammation and autoimmunity. 
Additional support for the autoimmune pathogenesis hypothesis 
is the finding that ALS has recently been included in the spectrum 
of neurologic manifestations associated with voltage-gated potas-
sium channel (VGKC) autoimmunity (23–25).
Because of the large body of evidence suggesting a neurotoxic 
effect of the immune response in ALS, numerous therapeutic tri-
als based on the autoimmune pathogenesis hypothesis have been 
performed. However, these studies have failed to demonstrate 
improvement in motor function. Immunosuppressive drugs, 
such as corticosteroids, azathioprine, cyclophosphamide, cyclo-
sporine, or combination pharmacotherapy, as well as immuno-
therapy with plasmapheresis or intravenous immunoglobulins, 
have not altered disease progression (26–28). Moreover, in what 
had been considered the ultimate trial in immunosuppression for 
ALS, total lymphoid irradiation (TLI), which produces a more 
powerful and prolonged immunosuppression, did not benefit 
patients with ALS (29). The conclusion from these therapeutic 
trials was that autoimmune mechanisms did not contribute to 
the pathogenesis in ALS. However, all negative trials based on 
the autoimmune pathogenesis hypothesis were performed in the 
latter decades of the 1900s, and TLI and the immunosuppressive 
drugs used in these early trials are no longer considered today’s 
gold standard in immunosuppression.
Since 1996, intensive immunosuppression followed by autolo-
gous hematopoietic stem cell transplantation (AHSCT) to renew 
the immune system has been used for the treatment of severe 
autoimmune diseases refractory to approved therapies (30). The 
largest cohort studied worldwide (European Group for Blood and 
Marrow Transplantation registry between 1996 and 2007) evalu-
ated the long-term outcomes of these transplants in 900 patients 
with various autoimmune diseases including multiple sclerosis, 
systemic sclerosis, systemic lupus erythematosus, rheumatoid 
arthritis, juvenile arthritis, and hematologic immune cytopenia 
(30). Among all patients, the 5-year survival was 85% and the 
progression-free survival 43%. Age <35 years and transplanta-
tion after the year 2000 were associated with progression-free 
survival. This worldwide study showed that profound immu-
nosuppression and AHSCT can induce sustained remissions in 
patients with severe systemic autoimmune diseases refractory 
to conventional therapy (30). Furthermore, it underscored the 
therapeutic principle that in all successfully treated autoimmune 
diseases, there are intractable cases that subsequently improve 
with more aggressive immunotherapy. Hence, the failure of prior 
ALS therapeutic trials based on the autoimmune pathogenesis 
hypotheses may have reflected a relative inability to achieve the 
intense immunosuppression needed to abolish the immune 
mechanisms contributing to disease progression.
In recent years, it has been recognized that stem cells have the 
ability to provide numerous potential benefits in ALS (31) and a 
variety of stem cell-based therapies are underway (32). The major-
ity of these studies have assessed the therapeutic efficacy of differ-
ent cellular delivery mechanisms, including intracranial, motor 
cortex, intrathecal, intraventricular, intraspinal, and intravenous, 
utilizing various types of stem cells to renew, repair, or replace 
damaged motor neurons. However, perhaps because of the earlier 
negative trials that discredited the autoimmune pathogenesis 
hypothesis, these stem cell trials do not emphasize immunosup-
pression as a therapeutic strategy. Rather, the injection of various 
types of stem cells into brain or spinal cord for the purpose of 
replacement or repair of damaged neurons, without antecedent 
immunosuppression, is perceived as holding the greatest potential 
for eventual success in the ALS patient (33). The omission of 
immunosuppression as a therapeutic strategy is problematic, since 
copious scientific studies support a role for neurotoxic effects of 
the immune response in ALS. Even the pioneers who used TLI 
and other immunosuppressive agents in the 1990s recognized 
that these agents did not completely abrogate cellular or antibody 
responses and that more powerful immunosuppression might 
still alter the course of ALS (34). Moreover, in a relatively recent 
study of allogeneic hematopoietic stem cell transplantation in 
ALS, transplantation preceded by only a non-myeloablative con-
ditioning regimen did not benefit ALS patients, despite reported 
engraftment of stem cells at sites of motor neuron pathology 
(35). This study provided evidence that stem cell transplantation 
in the absence of immunoablation may not deliver the greatest 
potential for success in the ALS patient. In this historical context, 
the current rush to inject stem cells into the central nervous 
system without antecedent immunosuppression seems premature 
because the most definitive trial in immunosuppression for ALS 
has not yet been performed. Accordingly, a step backward may be 
required to go forward in the therapeutic fight against ALS.
In this Opinion piece, we propose the use of immunoablation 
as a therapeutic strategy to abolish the potential neurotoxic effects 
of the immune response in ALS. It is not our intent to comment 
on the use of stem cells to renew, repair, or replace damaged 
motor neurons. In our therapeutic model, reinfused stem cells 
are required only to replenish or “reboot” the immune system. 
Without this step, patients undergoing immunoablation will die 
of opportunistic infections. Hence, immunoablation cannot be 
performed without subsequent stem cell infusion.
We are aware that there may be concern about submitting 
ALS patients to immunoablation. However, for almost 20 years, 
this type of intensive immunosuppression followed by stem cell 
transplantation has been used with success for the treatment of 
severe autoimmune diseases (30). Immunoablation and stem 
cell transplantation is also a standard of care in the treatment of 
hematological malignancies. In ALS patients, as in patients with 
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autoimmune diseases or hematological malignancies, immunoa-
blation would be expected to be followed by regeneration of a 
new self-tolerant immune system derived from the reinfused 
stem cells. The abundance of data suggesting that neuroinflam-
mation contributes to ALS pathogenesis warrants such a trial. 
The therapeutic concept that in all autoimmune diseases there 
are intractable cases that subsequently improve with more aggres-
sive immunotherapy also demands the most definitive trial of 
immunosuppression in ALS. Only then can the autoimmune 
pathogenesis hypothesis be revived or be laid to eternal rest.
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